{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:03:07Z","timestamp":1789786987504,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.jpba.2026.117716","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:54:20Z","timestamp":1787813660000},"page":"117716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Forced degradation studies reveal favorable stability of bispecific antibodies generated using the B-Body\u00ae platform"],"prefix":"10.1016","volume":"282","author":[{"given":"Xin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gawdzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah","family":"Woodall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Wiwczar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2026.117716_bib1","article-title":"Antibodies to watch in 2024, Antibodies to watch in 2024","volume":"16","author":"Crescioli","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117716_bib2","doi-asserted-by":"crossref","first-page":"E2656","DOI":"10.1073\/pnas.1401131111","article-title":"Origins of specificity and affinity in antibody\u2013protein interactions","volume":"111","author":"Peng","year":"2014","journal-title":"PNAS"},{"key":"10.1016\/j.jpba.2026.117716_bib3","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.abg1209","article-title":"Bispecific antibodies","volume":"372","author":"Brinkmann","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jpba.2026.117716_bib4","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2381261","article-title":"Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers","volume":"16","author":"Liao","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117716_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-017-0091-4","article-title":"Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment","volume":"6","author":"Yu","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.jpba.2026.117716_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"Knobs-into-holes\u2019 engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"key":"10.1016\/j.jpba.2026.117716_bib7","doi-asserted-by":"crossref","first-page":"14706","DOI":"10.1074\/jbc.M117.793497","article-title":"A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1","volume":"292","author":"Nardis","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2026.117716_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/19420862.2015.1007816","article-title":"Improving target cell specificity using a novel monovalent bispecific IgG design","volume":"7","author":"Mazor","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117716_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2273449","article-title":"Robust production of monovalent bispecific IgG antibodies through novel electrostatic steering mutations at the CH1-C\u03bb interface","volume":"15","author":"Bagert","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117716_bib10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymeth.2018.11.008","article-title":"Engineering therapeutic bispecific antibodies using CrossMab technology","volume":"154","author":"Klein","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.jpba.2026.117716_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1967714","article-title":"Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins","volume":"13","author":"Surowka","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117716_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-1759(00)00339-2","article-title":"Bispecific human IgG by design","volume":"248","author":"Carter","year":"2001","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jpba.2026.117716_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.biologicals.2016.06.005","article-title":"Determination of critical quality attributes for monoclonal antibodies using quality by design principles","volume":"44","author":"Alt","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.jpba.2026.117716_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","article-title":"Development of forced degradation and stability indicating studies of drugs\u2014A review","volume":"4","author":"Blessy","year":"2014","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2026.117716_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejpb.2015.10.016","article-title":"Forced degradation studies of biopharmaceuticals: Selection of stress conditions","volume":"98","author":"Tamizi","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jpba.2026.117716_bib16","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1080\/19420862.2017.1368602","article-title":"Forced degradation of recombinant monoclonal antibodies: A practical guide","volume":"9","author":"Nowak","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117716_bib17","doi-asserted-by":"crossref","first-page":"4703","DOI":"10.55248\/gengpi.4.523.42372","article-title":"A review of stability indicating methods and forced degradation studies","volume":"4","author":"Sonawane","year":"2023","journal-title":"Int. J. Res. Publ. Rev."},{"key":"10.1016\/j.jpba.2026.117716_bib18","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/19420862.2019.1618675","article-title":"Using bispecific antibodies in forced degradation studies to analyze the structure\u2013function relationships of symmetrically and asymmetrically modified antibodies","volume":"11","author":"Evans","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117716_bib19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1021\/acs.analchem.8b04071","article-title":"Rapid identification of disulfide bonds and cysteine-related variants in an IgG1 knob-into-hole bispecific antibody enhanced by machine learning","volume":"91","author":"Baker","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117716_bib20","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.xphs.2019.06.025","article-title":"Characterization of a novel bispecific antibody with improved conformational and chemical stability","volume":"109","author":"Petoskey","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117716_bib21","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1021\/acsomega.1c06305","article-title":"Detailed analytical characterization of a bispecific IgG1 CrossMab antibody of the knob-into-hole format applying various stress conditions revealed pronounced stability","volume":"7","author":"Grunert","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.jpba.2026.117716_bib22","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.xphs.2024.04.029","article-title":"Comprehensive stress stability studies reveal the prominent stability of the liquid-formulated biotherapeutic asymmetric monovalent bispecific IgG1 monoclonal antibody format","volume":"113","author":"Sankaran","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117716_bib23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/07388551.2021.1874281","article-title":"Stability testing in monoclonal antibodies","volume":"41","author":"Kaul","year":"2021","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.jpba.2026.117716_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2020.113207","article-title":"Coupling non-denaturing chromatography to mass spectrometry for the characterization of monoclonal antibodies and related products","volume":"185","author":"Farsang","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117716_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchromb.2004.12.033","article-title":"Non-enzymatic hinge region fragmentation of antibodies in solution","volume":"818","author":"Cordoba","year":"2005","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2026.117716_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4161\/mabs.3.3.15608","article-title":"R. Lonescu, Fragmentation of monoclonal antibodies","volume":"3","author":"Vlasak","year":"2011","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117716_bib27","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1080\/19420862.2017.1300214","article-title":"Glycation of antibodies: Modification, methods and potential effects on biological functions","volume":"9","author":"Wei","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117716_bib28","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.1021\/ac050672d","article-title":"Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies","volume":"77","author":"Chelius","year":"2005","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117716_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/19420862.2018.1548233","article-title":"Deamidation and isomerization liability analysis of 131 clinical-stage antibodies","volume":"11","author":"Lu","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117716_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s42003-018-0032-8","article-title":"Assessment of susceptible chemical modification sites of trastuzumab and endogenous human immunoglobulins at physiological conditions","volume":"1","author":"Schmid","year":"2018","journal-title":"Commun. Biol."},{"key":"10.1016\/j.jpba.2026.117716_bib31","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.molimm.2009.02.002","article-title":"Impact of methionine oxidation on the binding of human IgG1 to FcRn and Fc\u03b3 receptors","volume":"46","author":"Bertolotti-Ciarlet","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.jpba.2026.117716_bib32","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1002\/jps.23286","article-title":"U. Grausschopf, Analytical protein A chromatography as a quantitative tool for the screening of methionine oxidation in monoclonal antibodies","volume":"101","author":"Loew","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117716_bib33","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.4161\/mabs.29601","article-title":"A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies","volume":"6","author":"Stracke","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117716_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2026.117379","article-title":"A streamlined workflow for early phase formulation development of monoclonal antibodies comprising multi-attribute method and ligand binding assay","volume":"273","author":"Smith","year":"2026","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2026.117716_bib35","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1021\/ac404130a","article-title":"Understanding the conformational impact of chemical modifications on monoclonal antibodies with diverse sequence variation using hydrogen\/deuterium exchange mass spectrometry and structural modeling","volume":"86","author":"Zhang","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117716_bib36","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1021\/ac0494174","article-title":"vivo deamidation characterization of monoclonal antibody by LC\/MS\/MS","volume":"77","author":"Huang","year":"2005","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117716_bib37","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1002\/jps.21655","article-title":"Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1","volume":"98","author":"Yan","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117716_bib38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ab.2009.05.043","article-title":"Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody","volume":"392","author":"Vlasak","year":"2009","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jpba.2026.117716_bib39","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.1021\/acs.analchem.6b01958","article-title":"Understanding the impact of methionine oxidation on the biological functions of IgG1 antibodies using hydrogen\/deuterium exchange mass spectrometry","volume":"88","author":"Mo","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2026.117716_bib40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/pro.45","article-title":"Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn","volume":"18","author":"Pan","year":"2009","journal-title":"Protein Sci."},{"key":"10.1016\/j.jpba.2026.117716_bib41","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jps.24136","article-title":"Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation","volume":"104","author":"Gao","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117716_bib42","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1124\/dmd.111.039453","article-title":"Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences","volume":"39","author":"Wang","year":"2011","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.jpba.2026.117716_bib43","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1073\/pnas.1408766112","article-title":"Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics","volume":"112","author":"Schoch","year":"2015","journal-title":"PNAS"},{"key":"10.1016\/j.jpba.2026.117716_bib44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jpba.2026.117716_bib45","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.xphs.2021.11.024","article-title":"Oxidation and deamidation of monoclonal antibody products: Potential impact on stability, biological activity, and efficacy","volume":"111","author":"Gupta","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117716_bib46","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.xphs.2019.10.051","article-title":"Unique impacts of methionine oxidation, tryptophan oxidation, and asparagine deamidation on antibody stability and aggregation","volume":"109","author":"Alam","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2026.117716_bib47","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4161\/mabs.27876","article-title":"Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: susceptibility vs. functionality of critical quality attributes","volume":"6","author":"Haberger","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.jpba.2026.117716_bib48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jpba.2017.12.022","article-title":"Stability assessment of antibody-drug conjugate Trastuzumab emtansine in comparison to parent monoclonal antibody using orthogonal testing protocol","volume":"150","author":"Mohamed","year":"2018","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526003845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708526003845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:30:07Z","timestamp":1789785007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708526003845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":48,"alternative-id":["S0731708526003845"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117716","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Forced degradation studies reveal favorable stability of bispecific antibodies generated using the B-Body\u00ae platform","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2026.117716","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117716"}}